>

TGF beta (type I, short)

Q: Can I use the TGF beta (type I, short) icon in a BioRender figure or scientific illustration?

Yes — the TGF beta (type I, short) is fully integrated into BioRender's drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you're building from scratch or starting with a BioRender template.

Q: Can I export figures that include the TGF beta (type I, short) icon for publication or presentations?

Yes — figures containing the TGF beta (type I, short) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

TGF beta (type I, short) - Editable icon of a short TGF beta type 1 receptor with a ligand binding site and intracellular serine/threonine kinase domain

[{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a36/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a36/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a35/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a35/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a34/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a34/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a33/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a33/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a32/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a32/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a31/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a31/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a30/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a30/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a2f/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a2f/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a2e/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a2e/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a2d/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a2d/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a2c/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a2c/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a2b/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a2b/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a2a/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a2a/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a29/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a29/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a28/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a28/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a27/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a27/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a26/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a26/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a25/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a25/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a24/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a24/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a23/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a23/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a22/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a22/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a21/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a21/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a20/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a20/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a1f/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a1f/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a1e/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a1e/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a1d/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a1d/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a1c/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a1c/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a1b/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a1b/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a1a/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a1a/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a19/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a19/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a18/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a18/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a17/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a17/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a16/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a16/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a15/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a15/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a14/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a14/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a13/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a13/63331d69d8c4400021f6fa7c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6333325ef544890021309a12/63331d69d8c4400021f6fa7c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6333325ef544890021309a12/63331d69d8c4400021f6fa7c.png"}]

Keywords

keyword text

TGF beta,transforming growth factor beta,serine kinase receptor,TGF β,TGF,beta,threonine kinase receptor,kinase receptor,type I,type II,type 1,type 2,serine,threonine,kinase,short,proj-shortreceptor-icons-22q1,TGF

BioRender icons and templates meet journal, grant, and copyright standards. For AI-generated figures, policies vary. Learn More

More Icons like this one in

Related Categories

Back To Library Home

Join 1,500,000 other scientists on BioRender

Sign up for your free account and start creating scientific figures faster today

Sign Up Free

FAQs

What is BioRender?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this TGF beta (type I, short) icon along with our library of more than 30,000 life science icons.

Can I use this icon in a BioRender figure or scientific illustration?

Yes, the TGF beta (type I, short) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the TGF beta (type I, short) icon customizable in BioRender?

Most icons in BioRender, including the TGF beta (type I, short) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

How are scientists using the TGF beta (type I, short) icon in their work?

BioRender users often use the TGF beta (type I, short) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Proteins.

Can I export figures that include the TGF beta (type I, short) icon for publication or presentations?

Yes, figures containing the TGF beta (type I, short) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

Is the TGF beta (type I, short) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the TGF beta (type I, short) icon — especially those focused on Proteins. You can search BioRender’s template library or add this icon manually to any canvas.

Make scientific figures in minutes

TGF beta (type I, short)

Join 1,500,000 other scientists on BioRender

FAQs

Looking for science content?